Trials / Terminated
TerminatedNCT04372017
Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection
Randomized, Double-Blind, Controlled Trial of Hydroxychloroquine vs Placebo as Post-Exposure Prophylaxis Against COVID-19 Infection
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Sanford Health · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a prospective, double-blind, randomized, placebo-controlled study in two distinct cohorts to evaluate the efficacy and safety of hydroxychloroquine in the prevention of COVID-19 infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hydroxychloroquine | Participants randomized to hydroxychloroquine will take 800mg on day 1 followed by 400mg on days 2-5. |
| DIETARY_SUPPLEMENT | Vitamin D | Participants randomized to placebo will take IU1600 on day 1 and IU 800 on days 2-5. |
Timeline
- Start date
- 2020-05-14
- Primary completion
- 2021-06-04
- Completion
- 2021-06-04
- First posted
- 2020-05-01
- Last updated
- 2021-12-10
- Results posted
- 2021-12-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04372017. Inclusion in this directory is not an endorsement.